# A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

> clinical trial · VERIFIED · 2026-06-12

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Esophageal Squamous Cell Carcinoma

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05319730

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.